Investigational drug · Phase 3
Fosmanogepix
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Candidemia, Candidiasis, Invasive, Invasive Mold Infections.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "Fosmanogepix"
First trial start
2024
Dec 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fosmanogepix", any sponsor or status.
Conditions studied
As listed on its trial records.
- Candidemia
- Candidiasis, Invasive
- Invasive Mold Infections
Approved drugs for the same conditions: Fungal infections · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Fosmanogepix" as an intervention, largest first.
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Pivotal-lookingRecruiting
Basilea PharmaceuticaIndustry
NCT05421858 · 450 participants (planned) · Start Dec 11, 2024 · Primary completion Jan 30, 2028
Drug: Fosmanogepix; Fosmanogepix and 6 more · For: Candidemia; Candidiasis, Invasive
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 146 sites in all
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.Pivotal-lookingRecruiting
Basilea PharmaceuticaIndustry
NCT06925321 · 234 participants (planned) · Start Aug 26, 2025 · Primary completion Feb 2028
Drug: Fosmanogepix IV infusion; Standard of care antifungal therapy and 1 more · For: Invasive Mold Infections
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 90 sites in all
Basilea PharmaceuticaIndustry
NCT06961708 · 54 participants · Start Apr 14, 2025 · Primary completion Jul 15, 2025
Drug: Oral Fosmanogepix; IV Fosmanogepix and 2 more · For: Healthy
Sites: Shanghai, China
Basilea PharmaceuticaIndustry
NCT07881224 · 42 participants (planned) · Start Oct 1, 2026 · Primary completion Mar 9, 2027
Drug: Fosmanogepix · For: Healthy Adult Participants
Sites: Groningen, Netherlands
Basilea PharmaceuticaIndustry
NCT04166669 · 36 participants · Start Nov 12, 2019 · Primary completion Mar 3, 2020
Drug: APX001; Itraconazole and 1 more · For: Fungal Infection
Sites: Groningen, Netherlands · 2 sites in all
Basilea PharmaceuticaIndustry
NCT05582187 · 28 participants · Start Oct 31, 2022 · Primary completion Oct 16, 2025
Drug: Fosmanogepix · For: Hepatic Impairment
Sites: Rialto, California; Tampa, Florida
Basilea PharmaceuticaIndustry
NCT04240886 · 21 participants · Start Jan 4, 2020 · Primary completion Mar 29, 2022
Drug: fosmanogepix · For: Invasive Fungal Infections
Sites: Duarte, California; Durham, North Carolina; Brussels, Belgium · 15 sites in all
Basilea PharmaceuticaIndustry
NCT07916181 · 20 participants (planned) · Start Oct 27, 2026 · Primary completion Nov 1, 2027
Drug: Intravenous fosmanogepix; Intravenous fosmanogepix · For: End Stage Renal Disease on Dialysis; Adult
Sites: Orlando, Florida; Tampa, Florida
Basilea PharmaceuticaIndustry
NCT05491733 · 18 participants · Start Mar 2, 2021 · Primary completion May 13, 2021
Drug: APX001; APX001A · For: Invasive Fungal Infections
Sites: Salt Lake City, Utah
Basilea PharmaceuticaIndustry
NCT04148287 · 9 participants · Start Dec 13, 2019 · Primary completion Nov 30, 2020
Drug: APX001 · For: Candidemia; Invasive Candidiases; Candida Infection
Sites: Alberton, South Africa; Johannesburg, South Africa
Newest research
PubMed records naming it or its code names, newest first.
- Aspergillus -Mucorales co-infections: implications for first-line antifungal treatment?
Felber D, Hoenigl M, Prattes J, et al. · Curr Opin Infect Dis 2026
- Novel antifungal agents for treating endemic mycoses: hope on the horizon?
Bahr NC, Pasqualotto AC, Thompson GR · Curr Opin Infect Dis 2026
- CARD9 Deficiency in an Intractable Orbital Fungal Infection: A Case Report.
Bloch JF, Lionakis MS, Pottinger PS, et al. · Ophthalmic Plast Reconstr Surg 2026
- Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives.
Al-Zoubi RM, Farhan A, Hanbali B, et al. · Eur J Med Chem 2026
- Fosmanogepix-induced agranulocytosis.
Lortholary O, Blez D, Chantelot L, et al. · Antimicrob Agents Chemother 2026
- In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results.
Winkler ML, Kimbrough JH, Edeker S, et al. · Antimicrob Agents Chemother 2026
Also in development for Candidemia
- TMPSMX, Trimethoprim-sulfamethoxazolePhase 32 trials
Locus Biosciences · Urinary Tract Infections, Candidemia, Mycoses
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.